Daily Medication Pearl: Upadacitinib (Rinvoq)

Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis

Medication Pearl of the Day: Upadacitinib (Rinvoq)

Indication: Upadacitinib (Rinvoq)is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis.

Insight:

  • Dosing: The recommended dosage of Rinvoq is 15 mg once daily.
  • Dosage forms: Extended-release tablets 15 mg and 30 mg.
  • Adverse events: Adverse reactions (≥ 1%) were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, and acne.
  • Mechanism of action: JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
  • Manufacturer: AbbVie

Sources:

Microsoft Word - master-uspi-upadacitinib (rxabbvie.com)

rinvoq image - Google Search

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.